Comparative Pharmacology
Head-to-head clinical analysis: CECLOR versus CECLOR CD.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CECLOR versus CECLOR CD.
CECLOR vs CECLOR CD
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Cefaclor, a second-generation cephalosporin, inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), leading to cell lysis and death. It exhibits bactericidal activity against susceptible organisms.
Cefaclor, a second-generation cephalosporin, inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), thereby disrupting peptidoglycan cross-linking.
250 mg orally every 8 hours; for severe infections, 500 mg orally every 8 hours.
250-500 mg orally every 8 hours; extended-release form (CECLOR CD) 375-750 mg orally every 12 hours.
None Documented
None Documented
Terminal elimination half-life: 0.6-0.9 hours in adults with normal renal function. Prolonged to 2-3 hours in end-stage renal disease. Half-life does not increase significantly with hepatic impairment.
Terminal elimination half-life: ~0.6-0.9 hours (prolonged in renal impairment)
Primarily renal: 80-90% of unchanged drug excreted by glomerular filtration and tubular secretion within 8 hours. Biliary excretion accounts for <5%; fecal elimination negligible.
Renal: ~80% unchanged; biliary/fecal: ~20%
Category C
Category C
Cephalosporin Antibiotic
Cephalosporin Antibiotic